Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

What to do when standard therapy fails.

M Buti1, R Esteban

  • 1University General Hospital Valle de Hebron, Barcelona, Spain.

Forum (Genoa, Italy)
|March 16, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Downed woody debris carbon emissions in a European temperate virgin forest as driven by species, decay classes, diameter and microclimate.

The Science of the total environment·2023
Same author

Evolution of the consumption trend of proton pump inhibitors in the Lleida Health Region between 2002 and 2015.

BMC public health·2022
Same author

Prisons: an important link in the elimination of Hepatitis B.

Revista espanola de sanidad penitenciaria·2022
Same author

Is the universal population Hepatitis C virus screening a cost-effective strategy? A systematic review of the economic evidence.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2020
Same author

Trends in the consumption rates of benzodiazepines and benzodiazepine-related drugs in the health region of Lleida from 2002 to 2015.

BMC public health·2020
Same author

Health state utility values measured using the EuroQol 5-dimensions questionnaire in adults with chronic hepatitis C: a systematic literature review and meta-analysis.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation·2018
Same journal

The basis of allograft acceptance.

Forum (Genoa, Italy)·2011
Same journal

Recurrent liver disease after liver transplantation.

Forum (Genoa, Italy)·2011
Same journal

Integrated treatments for non-small cell lung cancer.

Forum (Genoa, Italy)·2006
Same journal

Gastrointestinal tumors.

Forum (Genoa, Italy)·2006
Same journal

Primary and metastatic brain tumors.

Forum (Genoa, Italy)·2006
Same journal

Impact of integrated treatments on patient management in solid tumors: from diagnosis to palliative care.

Forum (Genoa, Italy)·2006
See all related articles

Chronic hepatitis C patients not responding to interferon therapy may benefit from combination treatments. Interferon and ribavirin therapy shows sustained response rates, particularly for genotypes 2 and 3.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • A significant portion of chronic hepatitis C patients exhibit non-response to interferon (IFN) therapy.
  • Non-responders often present with advanced disease, including cirrhosis, higher viral loads, and genotype 1 infection, necessitating effective treatment strategies.
  • Re-treatment with standard or prolonged IFN monotherapy has not demonstrated sustained efficacy in non-responders.

Purpose of the Study:

  • To evaluate the efficacy of combination therapies for chronic hepatitis C non-responders.
  • To compare sustained response rates of combination therapy versus interferon monotherapy.
  • To identify patient subgroups that may benefit most from current combination treatment options.

Main Methods:

  • Review of existing studies on interferon (IFN) monotherapy and combination therapies for chronic hepatitis C non-responders.

Related Experiment Videos

  • Analysis of sustained virological and biochemical response rates based on treatment regimens, viral genotype, and presence of cirrhosis.
  • Assessment of preliminary data for novel combination therapies, including IFN, ribavirin, and amantadine.

    • Main Results:

    • Interferon monotherapy for over two years showed limited hepatic improvement in 20-40% of non-responders.
    • Six-month combination therapy with interferon and ribavirin achieved sustained response rates of 6-29%, varying by genotype and cirrhosis.
    • Genotypes 2 and 3 demonstrated higher sustained virological response probabilities compared to genotype 1.

    Conclusions:

    • Combination therapy, particularly with interferon and ribavirin, offers a beneficial treatment option for selected chronic hepatitis C non-responders.
    • Further research is ongoing to optimize combination therapy duration and dosage for improved outcomes.
    • Current evidence supports the recommendation of combination therapy for non-responders pending the availability of new therapeutic agents.